Prevalence of precancerous gynecological lesions and gynecological cancer in patients undergoing vaginal hysterectomy for pelvic organ prolapse

References

• Drutz HP, Alarab M. Pelvic organ prolapse: demographics and future growth prospects. Int Urogynecol J. 2006;17(S1):1–5. doi:10.1007/s00192-006-0102-1.
   Google Scholar
• Elbiaa AA, Abdelazim IA, Farghali MM, et al. Unexpected premalignant gynecological lesions in women undergoing vaginal hysterectomy for utero-vaginal prolapse. Prz Menopauzalny. 2015;14(3):188–191. doi:10.5114/pm.2015.54344.
   PubMedGoogle Scholar
• Grigoriadis T, Valla A, Zacharakis D, et al. Vaginal hysterectomy for uterovaginal prolapse: what is the incidence of concurrent gynecological malignancy? Int Urogynecol J. 2015;26(3):421–425. doi:10.1007/s00192-014-2516-5.
   PubMed Web of Science ®Google Scholar
• Renganathan A, Edwards R, Duckett JR. Uterus conserving prolapse surgery—what is the chance of missing a malignancy? Int Urogynecol J. 2010;21(7):819–821. doi:10.1007/s00192-010-1101-9.
   PubMed Web of Science ®Google Scholar
• Aydin S, Bakar RZ, Mammadzade A, et al. The incidence of concomitant precancerous lesions in cases who underwent hysterectomy for prolapse. J Clin Anal Med. 2016;7:676–680.
   Google Scholar
• Frick AC, Walters MD, Larkin KS, et al. Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse. Am J Obstet Gynecol. 2010;202(5):e1-507–e4. doi:10.1016/j.ajog.2010.01.077.
   Web of Science ®Google Scholar
• Ekici MA, Onal AC. Unexpected risk of gynecological malignant and premalignant disease in women undergoing hysterectomy for pelvic organ prolapse. Exp Biomed Res. 2020;3(1):56–62. doi:10.30714/j-ebr.2020157454.
   Google Scholar
• Pandey D, Inukollu PR, Shetty J, et al. Is it worth preserving the uterus? Unanticipated pathology in hysterectomy for pelvic organ prolapse (POP). Int J Reprod Contracept Obstet Gynecol. 2018;7(10):4145–4150. doi:10.18203/2320-1770.ijrcog20184143.
   Google Scholar
• Detollenaere RJ, DEN Boon J, Stekelenburg J, et al. Sacrospinous hysteropexy versus vaginal hysterectomy with suspension of the uterosacral ligaments in women with uterine prolapse stage 2 or higher: multicentre randomised non-inferiority trial. BMJ. 2015;351:h3717. doi:10.1136/bmj.h3717.
   PubMed Web of Science ®Google Scholar
• Haylen BT, Maher CF, Barber MD, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP). Int Urogynecol J. 2016;27(2):165–194. doi:10.1007/s00192-015-2932-1.
   PubMed Web of Science ®Google Scholar
• Sobczuk K, Sobczuk A. New classification system of endometrial hyperplasia WHO 2014 and its clinical implications. Prz Menopauzalny. 2017;16(3):107–111. doi:10.5114/pm.2017.70589.
   PubMedGoogle Scholar
• Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1–S27. doi:10.1097/LGT.0b013e318287d329.
   PubMed Web of Science ®Google Scholar
• Aimjirakul K, Ng JJ, Saraluck A, et al. A retrospective cohort study on the prevalence, risk factors, and improvement of overactive bladder symptoms in women with pelvic organ prolapse. Int J Women Health. 2023;15:1039–1046. doi:10.2147/IJWH.S413670.
   PubMed Web of Science ®Google Scholar
• Singer A. The uterine cervix from adolescence to the menopause. Br J Obstet Gynaecol. 1975;82(2):81–99. doi:10.1111/j.1471-0528.1975.tb02204.x.
   PubMedGoogle Scholar
• Koonmee S, Bychkov A, Shuangshoti S, et al. False-negative rate of papanicolaou testing: a national survey from the Thai society of cytology. Acta Cytol. 2017;61(6):434–440. doi:10.1159/000478770.
   PubMed Web of Science ®Google Scholar
• D'augè TG, Giannini A, Bogani G, et al. Prevention, screening, treatment and follow-up of gynecological cancers: state of art and future perspectives. CEOG. 2023;50(8):160.
   Google Scholar
• Zhang PY, Yu Y. Precise personalized medicine in gynecology cancer and infertility. Front Cell Dev Biol. 2019;7:382. doi:10.3389/fcell.2019.00382.
   PubMed Web of Science ®Google Scholar